TARGET AUDIENCE

Hematologists/oncologists, nurses, nurse practitioners (NPs), physicians assistants (PAs), pharmacists, and other healthcare professionals (HCPs) involved in the care of patients with hematological malignancies and disorders.

LEARNING OBJECTIVES

Upon completion of this activity, participants will: [LIST] [ITEM]Have increased knowledge regarding recent clinical trial data in hematologic malignancies and disorders from 2024 [ITEM]Demonstrate greater confidence in their ability to integrate recent data to personalize treatment for patients with hematologic malignancies and disorders [/LIST]

ACCREDITATION STATEMENTS

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO][MEDSCAPE]

[bold]For Full Conference Attendance: [/bold] [bold]For Physicians [/bold] Medscape, LLC designates this live activity for a maximum of 6.75 [italic]AMA PRA Category 1 Credit(s)™[/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Nurses[/bold] Awarded 6.75 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform. [bold]For Pharmacists [/bold] Medscape designates this continuing education activity for 6.75 contact hours (0.675 CEUs). (Universal Activity Number: JA0007105-0000-25-001-L01-P).